On May 28, Shenzhen Huada Zhizao Technology Co., Ltd. (hereinafter referred to as “Huada Zhizao”) announced the completion of more than 1 billion US dollars of round B financing. The leading investors were IDG Capital, CPE, Huaxing New Economic Fund, and the State Party. Capital, Huatai Zijin, Titanium Capital, Shanghai Sailing, Cornerstone Capital, Shanghai Dingfeng, Guotai Junan Venture Capital and other follow-up investment, old shareholders CITIC Securities / Jinshi Investment, Songhe Capital and other additional investments.
Huazhi Zhizhu mainly focuses on the gene sequencer known as the “Country of the Kingdom”. The company was established in April 2016 and was independently split from the original sequencer segment of Shenzhen Huada Group. This segment originated in 2013, when Huada acquired Complete Genomics in the United States to obtain core patented technology, and then formed a sequencer R & D team to implement domestic technology transformation.
The actual controller behind Huada Zhizao is Wang Jian, founder of Huada Group, with more than 1,000 employees, business in 50 countries and regions, and over 500 global customers. And has 8 branches around the world.
Introduced on the official website, Huada Zhizao focuses on the research, development, production and sales of related products such as instruments and equipment, reagents and consumables in the field of life sciences and medical health, providing real time , Full Picture and Life Long life digitalization complete equipment, to provide self-controllable advanced equipment, technical support and solutions for the actual needs of national medical and people’s livelihood, such as precision medicine, precision agriculture and precision health.
It is worth noting that this is the second round of large-scale financing completed by BGI after the first round of fundraising 1 year ago. Earlier on May 9, 2019, Huada Zhizao, which has been rumored to have started financing for nearly a year, finally completed a round of “blood transfusion”, disclosing that the first round of fundraising exceeded US $ 200 million. Multiple institutions.
Mu Feng, CEO of Huada Zhizao said this time, “Huada Zhizao, as an upstream company in the industry, hopes to continue to provide users with the core of life science research and application based on the life center rule. Tools to build an open and win-win industrial ecosystem. “Over the past year, with the DNBSEQ-T7 sequencer, high-throughput automated sample preparation system MGISP-960, remote ultrasonic robots and other products have been listed.
It is worth mentioning that during the new crown epidemic, Huada Zhizao related products also played an important role. In the early stage of the epidemic, BGI deployed two sets of DNBSEQ-T7Wuhan, assist in tracking and analyzing virus mutations. In addition, as of now, BGI has made high-throughput automated viral nucleic acid extraction equipment that has assisted medical institutions and disease control centers in more than 30 cities and regions in China, and has contributed to the theoretical extraction of more than 100,000 samples per day in the new crown virus detection the amount. In the “Fire Eye Laboratory” established by Huada, which aims to improve the detection capability of the local new crown, Huada Zhizao related equipment is also standard.